

## Gender differences in the prevalence of Parkinson's disease

\***Alexandra Zirra**<sup>1</sup> (orcid.org/0000-0003-3901-5456), \***Shilpa C Rao**<sup>2,3</sup> (orcid.org/0000-0002-2284-9203), **Jonathan Bestwick**<sup>1</sup> (orcid.org/0000-0002-3088-8616), **Rajasumi Rajalingam**<sup>4</sup> (orcid.org/0000-0002-2564-7375), **Connie Marras**<sup>4</sup> (orcid.org/0000-0002-9236-9328), **Cornelis Blauwendraat**<sup>5</sup> (orcid.org/0000-0001-9358-8111), **Ignacio Mata**<sup>2,3</sup> (orcid.org/0000-0002-6965-2977), and **Alastair J Noyce**<sup>1,6</sup> (orcid.org/0000-0003-3027-5497)

### \*Joint first authors

<sup>1</sup> Preventive Neurology Unit, Centre for Prevention, Detection and Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, UK

<sup>2</sup> Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic Foundation, Ohio, USA

<sup>3</sup> Case Western Reserve University, School of Medicine Department of Molecular Medicine Ohio, USA

<sup>4</sup> University Health Network, University of Toronto, Canada

<sup>5</sup> Laboratory of Neurogenetics, National Institute of Aging, National Institutes of Health, Bethesda, Maryland, USA

<sup>6</sup> Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, London, UK

**Correspondence:** Alastair Noyce, Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, EC1M 6BQ, email: [a.noyce@qmul.ac.uk](mailto:a.noyce@qmul.ac.uk)

**Keywords:** Parkinson's Disease, Meta-Analysis, Systematic Review, Prevalence, Gender Differences

**Relevant conflicts of interest/financial disclosures:** Nothing to report.

**Funding sources:** A.J.N. reports grants from the Barts Charity, Parkinson's UK, Aligning Science Across Parkinson's and Michael J. Fox Foundation, and the Virginia Keiley Benefaction. Personal fees/honoraria from Britannia, BIAL, AbbVie, Global Kinetics Corporation, Profile, Biogen, Roche, and UCB are outside of the submitted work. I.F.M. reports grants from Aligning Science Across Parkinson's and Michael J. Fox Foundation, The Parkinson's Foundation, American Parkinson Disease Association, and National Institutes of Health.

**Author contributions:** AJN and AZ contributed to conception and design of article. AZ and SR conducted the literature search. AJN coordinated the literature search and acted as a third reviewer. AZ and SR extracted data from included articles. AZ and JB analyzed the data. AZ and SR drafted the manuscript. AZ, SR, AJN, IM, CB, CM and RR were involved in revising the manuscript.

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## Abstract

**Background:** It is generally recognized that Parkinson's disease (PD) affects males more commonly than females. The reasons for the difference in PD prevalence by gender remain unclear.

**Methods:** In this systematic review and meta-analysis, we updated previous work by searching MEDLINE, SCOPUS, and OVID for articles reporting PD prevalence for both genders between 2011-2021. We calculated overall male/female prevalence ratios (OPR) and investigated heterogeneity in effect estimates.

**Results:** 19 new and 13 previous articles were included. The OPR was 1.18, 95% CI [1.03, 1.36]. The OPR was lowest in Asia and appeared to be decreasing over time. Study design, national wealth, and participant age did not explain heterogeneity in OPR.

**Conclusion:** Gender differences in PD prevalence may not be as stark as previously thought, but still remain. Studies are needed to understand the role of genetic, environmental, and societal determinants of gender differences in prevalence.

## Introduction

The burden of Parkinson's disease (PD) appears to be increasing and is estimated to reach 13 million PD cases by 2040.<sup>1</sup> In observational studies, PD tends to affect males more frequently than females but the reasons are unclear.<sup>2-5</sup> However, in some parts of the world (e.g. South Korea, Japan, Bolivia), a male predominance of PD is less apparent.<sup>6-8</sup> Variation in prevalence may be explained by case ascertainment (specialist access), social determinants (health beliefs, insurance), or risk factors (i.e. genetic, environmental factors, or their interaction).<sup>9-11</sup> Genetic factors are likely to be more prominent in patients with young-onset PD, defined by the age of onset <40 years. Male/female incidence and prevalence ratios for young-onset PD tend to be closer to 1,<sup>1,12,13</sup> and sex-stratified genome-wide association studies (GWAS) have not found significant differences between genders.<sup>14</sup>

Pringsheim *et al* demonstrated that the gender ratio for prevalence increased with advancing age and varied by continent (lowest in Asian countries).<sup>3</sup> In this systematic review and meta-analysis, we updated the knowledge about gender differences in PD prevalence, building on previous literature.<sup>3</sup> Additionally, we sought out to understand whether the study design, economic profile of the country, age at inclusion, or life expectancy could explain gender differences in PD prevalence.

## Methods

### Data selection

In this systematic review and meta-analysis, we searched for studies published from 2011-2021 with the terms: "Parkinson" and "prevalence"/"epidemiology" on MEDLINE, SCOPUS, and OVID (**Table S1**). Articles were included if they were population-based (door-to-door surveys and healthcare registry studies using PD diagnostic codes/medication), reported prevalence rates for males and females separately, and data were stratified by age groups. We excluded cohort studies because their design captures incidence typically, and case-control studies due to potential selection bias.<sup>15</sup> Other exclusion criteria were: lack of gender/age subgroup analysis, inclusion of secondary parkinsonism, and unavailable full-text.

Two independent reviewers (A.Z., S.C.R.) conducted the search and screened abstracts for eligibility. When differentially included, a third reviewer (A.J.N.) was involved. The list of selected prevalence studies was then combined with the list of studies in Pringsheim *et al*.<sup>3</sup>

### Data extraction

Extraction of prevalence data was performed by each reviewer including study reference, study design, target population, male/female prevalence, case numbers, total population by gender, and age group. Age-standardized or crude prevalence rates were used and converted to cases per 100,000 persons (**Supplementary material**).

Additional data were extracted from WHO life expectancy (LE) at birth from the year 2000 for studies published before this year and from the year 2010 for later studies.<sup>16</sup> The LE gap was calculated as the difference between gender (female LE minus male LE). Age at inclusion was extracted from articles either as reported (median) or was calculated from frequency tables (as the rank of the median).<sup>17</sup> World Bank data was used for the classification of high-income (HIC) and low/middle-income countries (L/MIC)<sup>18</sup>.

### Data analysis

Prevalence from each study was converted into a male/female ratio: OPR = overall male/female prevalence ratio with log transformation for normalization. A random-effects model was used due to high heterogeneity calculated by Cochran Q statistic and  $I^2$ . Subgroup meta-analysis and meta-regression were used to determine the significance of the different variables: study design, economic country profile, median age at study inclusion, LE gap, and study origin. For study origin Europe was used as the reference continent. STATA v.19 was used for statistical analysis and figures.

## Results

Our search identified 17,335 abstracts (**Figure 1A**). Titles and abstracts were screened for relevance, and to exclude case-control and cohort studies. From the first round, 350 articles were deemed relevant with 25 articles included for a full-text review after further exclusions. An in-depth review of the articles resulted in the exclusion of 6 articles due to insufficient data or no cases of PD identified for one gender (prevalence of 0). The final 19 articles from our search were added to the 13 articles from Pringsheim *et al* (**Figure 1B, Table S2, Supplementary References**).<sup>3</sup>

From the pooling effect estimates from a random-effects model of the 32 articles, we calculated an OPR of 1.18, 95% CI [1.03,1.36] with a high degree of heterogeneity ( $I^2=99.8%$ ) (**Figure S1A**). There was no evidence of small study bias ( $p = 0.562$ ; **Figure S1B**).

We explored the high heterogeneity observed in the data by considering study design (door-to-door survey versus health records analysis), national economic wealth (HIC versus L/MIC), and continent. Meta-regression for study design did not provide evidence that this was a source of heterogeneity ( $p = 0.141$ ). However, studies from L/MIC had a higher OPR of 1.28, 95% CI [1.16,1.4] compared to studies from HIC of 1.14, 95% CI [0.95,1.35]. When we looked at OPR between continents, Asia was found to have the smallest OPR, 1.04, 95% CI [0.83,1.29] (**Figure 2**). Meta-regression for categorical data - economic performance and continent, did not provide evidence that either were sources of heterogeneity ( $p = 0.362$  and  $p = 0.100$  for Asian compared to European studies, respectively).

Next, we investigated whether age at inclusion or LE gap could explain the heterogeneity. The median age for PD patients from the 32 studies was 75.4 (range 55-85). Meta-regression using median age did

not suggest that this was a source of observed heterogeneity ( $p = 0.059$ ). The LE gap also did not account for observed heterogeneity ( $p = 0.080$ ).

Lastly, we investigated whether OPR varied with publication year. A subgroup analysis showed a decreasing trend in the last 30 years: 1990-2000 OPR 2.06, 95% CI [0.72, 5.87], 2000-2010 OPR 1.24, 95% CI [1.06, 1.45] and 2010-present OPR 1.15, 95% CI [0.98, 1.35],  $p = 0.019$  (**Figure S2**).

## Discussion

This systematic review and meta-analysis demonstrated that the male/female prevalence ratio for PD is lower than has previously been reported by other studies.<sup>2</sup> The lowest male/female ratio was seen in studies from Asia. We also observed that OPR may be decreasing over time and that it was higher in L/MIC compared with HIC.

Large population-based studies are best suited for determining the prevalence of diseases like PD.<sup>15</sup> We included data from healthcare registries and door-to-door cross-sectional studies. Healthcare registries may cover 50-100% of a particular population,<sup>6,19</sup> thus for population-based prevalence estimates, door-to-door studies are considered the gold standard. PD diagnostic criteria vary across regions and institutions, causing potential differences in prevalence estimates for door-to-door and healthcare registries.<sup>19,20</sup> Our analysis did not identify study design as a source of heterogeneity in prevalence ratios.

There was little evidence to suggest that age at inclusion (AAO) might explain differences in gender ratio. Previous studies have suggested that in patients with younger AAO, the ratio is closer to 1.<sup>2</sup> One might expect that a younger AAO may arise to a greater contribution from genetic factors. GWAS studies to date, have not identified different genetic risk factors for PD between sexes,<sup>14</sup> but these studies over-represent participants of European ancestry and have lower female inclusion rates.<sup>9</sup> Efforts to create large trans-ethnic genomic datasets will help us to better understand PD genetics in under-represented populations.<sup>21</sup>

A source of heterogeneity that we were unable to explore properly was the role of environmental factors. Rural living and occupational pesticide exposure are associated with an increase in PD risk.<sup>22,23</sup> Males have traditionally held agricultural occupations, which could explain the higher male PD prevalence.<sup>24</sup> Increasing urbanization decreases in agriculture, and organophosphate use in some regions may explain a diminishing OPR. Other putative risks/protective factors, including the Mediterranean diet, type 2 diabetes, smoking, and alcohol consumption,<sup>25-30</sup> might contribute to the male predominance of PD.

Healthcare inequalities could account for observed differences in male/female PD prevalence. In L/MIC, such as Benin, 60% of females reported socioeconomic and marital barriers to accessing healthcare.<sup>31,32</sup> Stigma related to PD symptoms and cultural beliefs about 'normal' aging/PD

awareness may explain the different levels of healthcare access globally.<sup>33</sup> Our data showed that studies from L/MIC have a higher OPR, which may reflect unequal access to healthcare between genders.

Another important consideration is the relationship between disease prevalence, incidence, and survival. Females have a higher AAO and a lower incidence of PD but also have a longer LE than males.<sup>34</sup> Female longevity may influence the male/female prevalence imbalance in other neurodegenerative diseases, like Alzheimer's.<sup>35</sup> Our analysis did not support this hypothesis as life expectancy did not explain heterogeneity in OPR. However, the LE gap has changed over time,<sup>36</sup> and this may partly explain why the OPR is also seen to be decreasing in the last 30 years. The recent decrease in life expectancy gap may be related to environmental exposure, such as increased smoking rates in the female population<sup>37</sup> or the increasing integration of females into jobs traditionally held by males. Further studies are needed to understand the effect of LE and environmental/societal factors on PD prevalence.

A limitation of our study was not conducting the search prior to 2011. Consequently, we included both door-to-door studies - similar to Pringsheim *et al.*, as well as studies with the newer methodology of predictive algorithms. However, no significant difference was detected between the newly identified studies and those from Pringsheim *et al.*<sup>3</sup> Another limitation in our study was the use of both crude and age-standardized prevalence ratios. A third limitation was classifying the articles by geographic region since PD is a multifactorial disease in which genetics, environmental, and demographic factors may vary even between countries from the same region.<sup>38</sup> This may have impacted our results and further studies of differences within regions are needed.

In conclusion, this systematic review and meta-analysis shows that the gender ratio for PD prevalence is lower in Asian populations and may have been decreasing in recent years. Further high-quality epidemiological studies of diverse populations are needed to understand whether the effect stems from environmental, societal, and/or genetic factors.

## References

1. Dorsey, E. R. & Bloem, B. R. The Parkinson Pandemic-A Call to Action. *JAMA Neurol.* **75**, 9–10 (2018).
2. GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* **17**, 939–953 (2018).
3. Pringsheim, T., Jette, N., Frolkis, A. & Steeves, T. D. L. The prevalence of Parkinson's disease: a systematic review and meta-analysis. *Mov. Disord.* **29**, 1583–1590 (2014).
4. Ma, C.-L. *et al.* The prevalence and incidence of Parkinson's disease in China: a systematic review and meta-analysis. *J. Neural Transm.* **121**, 123–134 (2014).
5. Riccò, M. *et al.* Prevalence of Parkinson Disease in Italy: a systematic review and meta-analysis. *Acta Biomed.* **91**, e2020088 (2020).
6. Park, J.-H. *et al.* Trends in the incidence and prevalence of Parkinson's disease in Korea: a nationwide, population-based study. *BMC Geriatr.* **19**, 320 (2019).
7. Osaki, Y., Morita, Y., Kuwahara, T., Miyano, I. & Doi, Y. Prevalence of Parkinson's disease and atypical parkinsonian syndromes in a rural Japanese district. *Acta Neurol. Scand.* **124**, 182–187 (2011).
8. Nicoletti, A. *et al.* Prevalence of Parkinson's disease: a door-to-door survey in rural Bolivia. *Parkinsonism Relat. Disord.* **10**, 19–21 (2003).
9. Nalls, M. A. *et al.* Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurol.* **18**, 1091–1102 (2019).
10. Ascherio, A. & Schwarzschild, M. A. The epidemiology of Parkinson's disease: risk factors and prevention. *Lancet Neurol.* **15**, 1257–1272 (2016).
11. Elbaz, A., Carcaillon, L., Kab, S. & Moisan, F. Epidemiology of Parkinson's disease. *Rev. Neurol.* **172**, 14–26 (2016).
12. Moisan, F. *et al.* Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis. *J. Neurol. Neurosurg. Psychiatry* **87**, 952–957 (2016).
13. Brakedal, B., Toker, L., Haugarvoll, K. & Tzoulis, C. A nationwide study of the incidence, prevalence and mortality of Parkinson's disease in the Norwegian population. *NPJ Parkinsons Dis* **8**, 19 (2022).
14. Blauwendraat, C. *et al.* Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and  $\alpha$ -synuclein mechanisms. *Mov. Disord.* **34**, 866–875 (2019).
15. Belbasis, L. & Bellou, V. Introduction to Epidemiological Studies. *Methods Mol. Biol.* **1793**, 1–6 (2018).

16. Life expectancy at birth (years).  
[https://www.who.int/data/gho/data/indicators/indicator-details/GHO/life-expectancy-at-birth-\(years\)](https://www.who.int/data/gho/data/indicators/indicator-details/GHO/life-expectancy-at-birth-(years)).
17. Ch 3. Numbers about Numbers / SWT. <https://brownmath.com/swt/chap03.htm>.
18. Data Catalog. <https://datacatalog.worldbank.org>.
19. Nerius, M., Fink, A. & Doblhammer, G. Parkinson's disease in Germany: prevalence and incidence based on health claims data. *Acta Neurol. Scand.* **136**, 386–392 (2017).
20. de Rijk, M. C. *et al.* A population perspective on diagnostic criteria for Parkinson's disease. *Neurology* **48**, 1277–1281 (1997).
21. Global Parkinson's Genetics Program. GP2: The Global Parkinson's Genetics Program. *Mov. Disord.* **36**, 842–851 (2021).
22. Ritz, B. R., Paul, K. C. & Bronstein, J. M. Of Pesticides and Men: a California Story of Genes and Environment in Parkinson's Disease. *Curr Environ Health Rep* **3**, 40–52 (2016).
23. Narayan, S., Liew, Z., Bronstein, J. M. & Ritz, B. Occupational pesticide use and Parkinson's disease in the Parkinson Environment Gene (PEG) study. *Environ. Int.* **107**, 266–273 (2017).
24. Semchuk, K. M., Love, E. J. & Lee, R. G. Parkinson's disease and exposure to agricultural work and pesticide chemicals. *Neurology* **42**, 1328–1335 (1992).
25. Maraki, M. I. *et al.* Mediterranean diet adherence is related to reduced probability of prodromal Parkinson's disease. *Mov. Disord.* **34**, 48–57 (2019).
26. Gao, X. *et al.* Prospective study of dietary pattern and risk of Parkinson disease. *Am. J. Clin. Nutr.* **86**, 1486–1494 (2007).
27. Li, X., Li, W., Liu, G., Shen, X. & Tang, Y. Association between cigarette smoking and Parkinson's disease: A meta-analysis. *Arch. Gerontol. Geriatr.* **61**, 510–516 (2015).
28. Gallo, V. *et al.* Exploring causality of the association between smoking and Parkinson's disease. *Int. J. Epidemiol.* **48**, 912–925 (2019).
29. Kim, R., Yoo, D., Jung, Y. J., Han, K. & Lee, J.-Y. Sex differences in smoking, alcohol consumption, and risk of Parkinson's disease: A nationwide cohort study. *Parkinsonism Relat. Disord.* **71**, 60–65 (2020).
30. Choi, H. K. & Curhan, G. Beer, liquor, and wine consumption and serum uric acid level: the Third National Health and Nutrition Examination Survey. *Arthritis Rheum.* **51**, 1023–1029 (2004).
31. Zegeye, B. *et al.* Breaking Barriers to Healthcare Access: A Multilevel Analysis of Individual- and Community-Level Factors Affecting Women's Access to Healthcare Services in Benin. *Int. J. Environ. Res. Public Health* **18**, (2021).
32. Matin, B. K. *et al.* Barriers in access to healthcare for women with disabilities: a systematic review in qualitative studies. *BMC Womens. Health* **21**, 44 (2021).
33. Mshana, G., Dotchin, C. L. & Walker, R. W. 'We call it the shaking illness': perceptions and



- experiences of Parkinson's disease in rural northern Tanzania. *BMC Public Health* **11**, 219 (2011).
34. Haaxma, C. A. *et al.* Gender differences in Parkinson's disease. *J. Neurol. Neurosurg. Psychiatry* **78**, 819–824 (2007).
  35. Riedel, B. C., Thompson, P. M. & Brinton, R. D. Age, APOE and sex: Triad of risk of Alzheimer's disease. *J. Steroid Biochem. Mol. Biol.* **160**, 134–147 (2016).
  36. GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. *Lancet* **396**, 1160–1203 (2020).
  37. Janssen, F. Changing contribution of smoking to the sex differences in life expectancy in Europe, 1950-2014. *Eur. J. Epidemiol.* **35**, 835–841 (2020).
  38. Lim, S.-Y. *et al.* Parkinson's disease in the Western Pacific Region. *Lancet Neurol.* **18**, 865–879 (2019).

## Figures and tables

Figure 1. PRISMA Flow diagram of article selection and final count of articles selected





Table 1: (A) Results from search strategy (B) Final results from search strategy included a total of 19 articles from 2011 to 2021. These were added to the list of articles from Prinsheim *et al.*, totaling 32 articles from the years 1985 to 2021.

**Figure 2. Subgroup meta-analysis using random effects model for each study continent in the M/F prevalence ratio.**



NOTE: Weights and between-subgroup heterogeneity test are from random-effects model

Random effects meta-analysis with Cochrane Q statistic of the male/female prevalence ratio of each study categorized by the study's respective continent. The pooled prevalence ratio for all the studies is 1.18, 95% CI [1.03, 1.36], but heterogeneity is high between groups ( $I^2 = 99.8\%$ ,  $p = 0.013$ ).

## Supplementary

Raw data: "Prevalence v5.pdf".

Code repository: "Prevalence MA code.pdf".

### Supplementary Table S1. Search strategies for MEDLINE, SCOPUS and OVID.


DATABASE	SEARCH STRATEGY
MEDLINE	"Parkinson disease"[All Fields] AND "prevalence"[All Fields]; Filters: Journal Article, English, MEDLINE, from 2011/1/1 - 2021/12/30 Sort by: Most Recent
	"Parkinson disease"[All Fields] AND "epidemiology"[All Fields]; Filters: Journal Article, English, MEDLINE, from 2011/1/1 - 2021/12/30 Sort by: Most Recent
SCOPUS	( TITLE-ABS-KEY ( {Parkinson disease} AND {prevalence} ) AND LANGUAGE ( English ) ) AND PUBYEAR > 2011
	( TITLE-ABS-KEY ( {Parkinson disease} AND {epidemiology} ) AND LANGUAGE ( English ) ) AND PUBYEAR > 2011
OVID	"Parkinson disease" AND "prevalence" {Including Limited Related Terms}; Ovid, 2011 to current, English
	"Parkinson disease" AND "epidemiology" {Including Limited Related Terms}; Ovid, 2011 to current, English

**Table S2. List of included prevalence studies with study characteristics.**

Author, year	OPR	CI		Age*	M life exp	F life exp	F-M survival difference	Age group	Study type	Continent
Orozco, 2020	1.23	1.15	1.32	73	74	80.15	6.15	30+	P	S America
Eusebi, 2019	0.99	0.94	1.05	82	79.47	84.22	4.75	40+	P	Europe
Han, 2019	0.98	0.96	0.99	72	77.12	83.78	6.66	0+	P	Asia
Park, 2019	0.63	0.63	0.64	85	77.12	83.78	6.66	0+	P	Asia
Fleury, 2018	1.45	1.44	1.46	75	80.03	84.18	4.15	0+	P	Europe
Kadastik-Erme, 2018	1.21	0.99	1.47	77	70.86	80.45	9.59	0+	P	Europe
Marras, 2018	1.37	1.34	1.39	80	78.56	80.8	2.24	45+	P	N America
Valent, 2018	1.28	1.21	1.35	77	79.47	84.22	4.75	0+	P	Europe
Nerius, 2017	1.05	0.99	1.11	77	77.78	82.54	4.76	0+	P	Europe
Khan, 2016	1.77	0.47	6.64	72	61.53	63.9	2.37	50+	S	Asia
Blin, 2015	0.97	0.97	0.98	80	77.96	84.34	6.38	18+	P	Europe
Khedr, 2015	1.39	0.71	2.72	67	67.82	72.69	4.87	0+	S	Africa
Yang, 2015	1.31	0.86	2.00	70	72.26	77.94	5.68	0+	S	Asia
Zou, 2014	1.67	0.75	3.74	85	72.26	77.94	5.68	70+	P	Asia
El-Tallawy, 2013	1.32	0.66	2.66	65	67.82	72.69	4.87	40+	S	Africa
Gordon, 2012	1.45	1.34	1.57	70	78.56	80.8	2.24	40+	P	N America
Lökk, 2012	1.19	1.11	1.26	74	79.41	83.15	3.74	0+	P	Europe
Seijo-Martinez, 2011	2.09	0.75	5.81	80	78.76	84.58	5.82	65+	S	Europe
Osaki, 2011	0.68	0.47	0.99	75	79.46	85.77	6.31	0+	P	Asia
Das, 2008	0.48	0.18	1.28	80	65.69	68.94	3.25	60+	S	India
Barbosa, 2006	1.27	0.68	2.36	82	70.57	77.98	7.41	65+	S	S America
Zhang, 2005	1.17	0.92	1.48	80	72.26	77.94	5.68	55+	S	Asia
Zhang b, 2005	1.34	0.88	2.04	63	72.26	77.94	5.68	50+	S	Asia
Bergareche, 2004	0.81	0.31	2.15	80	78.76	84.58	5.82	65+	S	Europe
Tan, 2004	1.55	0.87	2.77	75	79.36	84.01	4.65	50+	S	Asia
Benito-Leon, 2003	1.58	1.03	2.44	77	78.76	84.58	5.82	65+	S	Europe
Nicoletti, 2003	0.77	0.13	4.58	55	79.47	84.22	4.75	40+	S	Europe
Zhang, 2003	1.09	0.67	1.78	80	72.26	77.94	5.68	55+	S	Asia
Kis, 2002	2.86	0.93	8.78	80	79.47	84.22	4.75	60+	S	Europe
Wang, 1996	1.08	0.48	2.45	71.3	69.34	74.15	4.81	50+	S	Asia
Trenkwalder, 1995	3.74	0.73	19.16	78	75.04	80.92	5.88	65+	S	Europe
Wang, 1994	5.66	0.67	48.12	76.5	69.34	74.15	4.81	50+	S	Asia


OPR – overall male to female prevalence ratio; CI – confidence interval; exp – expectancy; F – female; M – male; P – predictive, S – survey. \* age of inclusion is recorded as median. Life expectancy values for each gender were extracted from WHO life expectancy (LE) at birth from the year 2000 for studies published before this year and from the year 2010 for later studies.

### Supplementary Figure S1. Meta-funnel plot analyses for reporting bias in prevalence studies



(A) Meta-analysis using random effects and Cochran Q statistic for male/female prevalence ratios with an overall prevalence ratio of 1.18, 95% CI [1.03,1.36]. (B) Metafunnel plot of included studies did not identify any evidence of small studying reporting bias ( $p = 0.562$ ).

Supplementary Figure S2. Subgroup meta-analysis using random effects model for time-trends in the M/F prevalence ratio.



NOTE: Weights and between-subgroup heterogeneity test are from random-effects model

Random effects meta-analysis with Cochrane Q statistic of the M/F prevalence ratio of each study categorized by the year of publication. This shows a decreasing trend from 2.06, 95% CI [0.72, 5.87] in 1990-2000 to 1.24, 95% CI [1.06, 1.45] in 2000-2010, and to 1.15, 95% CI [0.98, 1.35] in 2010-2021.

Supplementary references:

- S1. Orozco, J.L. *et al.* Parkinson's disease prevalence, age distribution and staging in Colombia. *Neurol Int.* 2020 Jul 10;12(1):8401.
- S2. Eusebi, P. *et al.* Incidence and prevalence of Parkinson's disease in the Italian region of Umbria: a population-based study using healthcare administrative databases. *Neurol Sci.* 2019 Aug;40(8):1709-1712.
- S3. Han, S. *et al.* Prevalence and incidence of Parkinson's disease and drug-induced parkinsonism in Korea. *BMC Public Health.* 2019 Oct 22;19(1):1328.
- S4. Park, JH. *et al.* Trends in the incidence and prevalence of Parkinson's disease in Korea: a nationwide, population-based study. *BMC Geriatr* 19, 320 (2019).
- S5. Fleury, V. *et al.* Descriptive epidemiology of parkinsonism in the Canton of Geneva, Switzerland. *Parkinsonism Relat Disord.* 2018 Sep;54:30-39.
- S6. Kadastik-Eerme, L. *et al.* The increasing prevalence of Parkinson's disease in Estonia. *Acta Neurol Scand.* 2018 Sep;138(3):251-258.
- S7. Marras, C. *et al.* Parkinson's Foundation P4 Group. Prevalence of Parkinson's disease across North America. *NPJ Parkinsons Dis.* 2018 Jul 10;4:21.
- S8. Valent, F. *et al.* The epidemiology of Parkinson's disease in the Italian region Friuli Venezia Giulia: a population-based study with administrative data. *Neurol Sci.* 2018 Apr;39(4):699-704.
- S9. Nerius, M. *et al.* Parkinson's disease in Germany: prevalence and incidence based on health claims data. *Acta Neurol Scand.* 2017 Nov;136(5):386-392.
- S10. Khan, S. *et al.* A door-to-door survey to estimate the prevalence of Parkinsonism in Pakistan. *Neuropsychiatr Dis Treat.* 2016 Jun 21;12:1499-506.
- S11. Blin, P. *et al.* Parkinson's disease incidence and prevalence assessment in France using the national healthcare insurance database. *Eur J Neurol.* 2015 Mar;22(3):464-71.
- S12. Khedr, E.M. *et al.* Prevalence of Parkinsonism and Parkinson's disease in Qena governorate/Egypt: a cross-sectional community-based survey. *Neurol Res.* 2015 Jul;37(7):607-18.
- S13. Yang, X.L. *et al.* Related factors and prevalence of Parkinson's disease among Uygur residents in Hetian, Xinjiang Uygur Autonomous Region. *Genet Mol Res.* 2015 Jul 31;14(3):8539-46.
- S14. Gordon, PH *et al.* Parkinson's disease among American Indians and Alaska natives: a nationwide prevalence study. *Mov Disord.* 2012 Sep 15;27(11):1456-9.
- S15. Lökk, J. *et al.* Drug and treatment costs in Parkinson's disease patients in Sweden. *Acta Neurol Scand.* 2012 Feb;125(2):142-7.
- S16. Seijo-Martinez, M. *et al.* Prevalence of parkinsonism and Parkinson's disease in the Arosa Island (Spain): a community-based door-to-door survey. *J Neurol Sci.* 2011 May 15;304(1-2):49-54.



- S17. Osaki, Y. *et al.* Prevalence of Parkinson's disease and atypical parkinsonian syndromes in a rural Japanese district. *Acta Neurol Scand.* 2011 Sep;124(3):182-7.
- S18. El-Tallawy, H.N. *et al.* Prevalence of Parkinson's disease and other types of Parkinsonism in Al Kharga district, Egypt. *Neuropsychiatr Dis Treat.* 2013;9:1821-6.
- S19. Zou, Y.M. *et al.* The prevalence of Parkinson's disease continues to rise after 80 years of age: a cross-sectional study of Chinese veterans. *Eur Rev Med Pharmacol Sci.* 2014;18(24): 3908-15.
- S20. Das, S.K. *et al.* Prevalence of major neurological disorders among geriatric population in the metropolitan city of Kolkata. *J Assoc Physicians India* 2008;56:175-181.
- S21. Barbosa, M.T. *et al.* Parkinsonism and Parkinson's disease in the elderly: a community-based survey in Brazil (the Bambui study). *Mov Disord* 2006;21:800-808.
- S22. Zhang, Z.X. *et al.* Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai. *Lancet* 2005;365:595-597.
- S23. Zhang, L. *et al.* The prevalence of PD in a nutritionally deficient rural population in China. *Acta Neurol Scand* 2005;112:29-35.
- S24. Bergareche, A. *et al.* Prevalence of Parkinson's disease and other types of Parkinsonism: a door-to-door survey in Bidasoa, Spain. *J Neurol* 2004;251:340-345.
- S25. Tan, L.C.S. *et al.* Prevalence of Parkinson disease in Singapore: Chinese vs Malays vs Indians. *Neurology* 2004;62:1999-2004.
- S26. Benito-Leon, J. *et al.* Neurological Disorders in Central Spain (NEDICES) Study Group. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. *Mov Disord* 2003;18:267-274.
- S27. Nicoletti, A. *et al.* Prevalence of Parkinson's disease: a door-to-door survey in rural Bolivia. *Parkinsonism Relat Disord* 2003;10:19-21.
- S28. Zhang, Z.X. *et al.* Prevalence of Parkinson's disease and related disorders in the elderly population of greater Beijing, China. *Mov Disord* 2003;18:764-772.
- S29. Kis, B. *et al.* Novel three-stage ascertainment method: prevalence of PD and parkinsonism in South Tyrol, Italy. *Neurology* 2002;58:1820-1825.
- S30. Wang, S.J. *et al.* A door-to-door survey of Parkinson's disease in a Chinese population in kinmen. *Arch Neurol* 1996;53:66-71.
- S31. Trenkwalder, C. *et al.* Starnberg trial on epidemiology of Parkinsonism and hypertension in the elderly: prevalence of Parkinson's disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. *Arch Neurol* 1995;52:1017-1022.
- S32. Wang, S.J. *et al.* Parkinson's disease in Kin-Hu, Kinmen: a community survey by neurologists. *Neuroepidemiology* 1994;13:69-74.